Atlas Trials

A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease

Clinical trial NCT03575052 · COMPLETED

Trial details

NCT number
NCT03575052
Sponsor
ACADIA Pharmaceuticals Inc.
Status
COMPLETED
Phase
Phase 3
Study type
INTERVENTIONAL
Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Start date
2018-05-21
Primary completion
2022-05-06
Enrollment
784

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.